《大行报告》摩通首予德琪医药-B(06996.HK)「增持」评级 目标价30元
摩根大通发表报告,首次覆盖研究德琪医药-B(06996.HK),予其「增持」评级,目标价30元。
该行表示,德琪医药是亚太区处临床阶段的生物制药商,其致力於研发治疗癌症的创新药。集团已策略性地建立一个高度选择性及差异化的产品线,由12款具有合并可能的候选药物组成,其中包括两款针对大量未获满足医疗需求的後期临床资产。另外,德琪医药亦有点对点的综合平台,采用组合及互补的研发策略,以最大化其产品线的潜力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.